Latest Conference Coverage

STOP 301 Study of INP104 for Migraine: Carrie Dougherty, MD, FAHS

The program director of the Medstar Georgetown University Hospital Headache Medicine Fellowship program discussed the findings of the STOP 301 study.

External Trigeminal Nerve Stimulation Proves Safety, Efficacy in Migraine Treatment

Using the FDA-approved Cefaly device, the TEAM study data suggest that the device can be applied as a safe alternative to pharmacological treatments in the acute treatment of migraine.

Collecting Drug-Drug Interaction Data on Rimegepant: Elyse Stock, MD

The chief medical officer of Biohaven Pharmaceuticals discussed the findings of an assessment of rimegepant (Nurtec ODT) exposure with concomitant administration of inhibitors of P-gp and BCRP transporters.

Early Response to Eptinezumab Predicts Continued Response in Chronic Migraine

An assessment of data from the PROMISE-2 trial suggests that individuals who respond to treatment in the first month are likely to maintain their response through at least 6 months.

Real-World Use of CGRPs in Combination With OnabotulinumtoxinA: Andrew M. Blumenfeld, MD

The director of the Headache Center of Southern California discussed his research from AHS 2021 which evaluated safety and efficacy of combined treatment with CGRPs and onabotulimtoxinA.

Combination GCRP Monoclonal Antibody and Gepant Treatment Shows Safety, Efficacy

Open-label data of concomitant use of CGRP monoclonal antibodies and receptor antagonists suggest that the agents can be safely and effectively combined in the treatment of migraine.

Nearly Half of Patients With Migraine Hesitate to Seek Care

The reported reasons included wanting to take care of symptoms themselves, concern that migraine will not be taken seriously, and believing migraines are not severe or painful enough to seek care.

Eptinezumab Reduces Severity, Burdensome Features of Headache Episodes

Treatment with eptinezumab resulted in reduced burdensome features of headache episodes including severe pain, photophobia, phonophobia, nausea, and limited physical activity.

Survey Suggests Need for Migraine Treatment Standardization Among Women’s Healthcare Providers

Respondents reported varying levels of comfort regarding the management of migraine during pregnancy, with only half of women’s healthcare providers indicating they conducted counseling on migraine during pregnancy.

Lasmiditan Efficacious in Patients With Insufficient Triptan Response

Investigators’ analysis of a subset of patients with insufficient response from the CENTURION study suggests that the acute agent from Eli Lilly offers potential in this population.

INP104 Continues to Show Promising Efficacy in Acute Migraine Treatment

Treatment with INP104 was associated with high rates of symptoms freedom and may be a promising new acute treatment for patients with migraine.

Consensus Reached on Updates for ICHD-3 Criteria for Posttraumatic Headache

Experts were in agreement that the criteria should include PTH phenotype, TBI mechanism and TBI comorbidities.

Intranasal DHE Agent INP104 Displays Safety for Migraine Treatment

The nasal delivery of dihydroergotamine also showed a lower incidence of nausea than IV-administrated dihydroergotamine.

Rimegepant, Ubrogepant, Lasmiditan All Safe and Effective for Acute Migraine Treatment

Rimegepant (Nurtec ODT; Biohaven) had the lowest number needed to treat for sustained pain freedom from migraine.

Atogepant Sustains 1-Year Efficacy in Migraine in Extension Trial

ATA188’s Potential in Progressive MS: Jakob Dupont, MD, MA

The head of global research and executive vice president of Atara Biotherapeutics discussed improvements seen in patients treated with the investigational therapy.

Developing the aT2-LV Biomarker for Progressive MS

Robert Zivadinov, MD, PhD, professor of neurology and director of the Buffalo Neuroimaging Analysis Center, discussed the post-hoc analysis of the ORATORIO trial he and colleagues conducted.

What to Expect From the 2021 American Headache Society Annual Scientific Meeting

With the AHS 63rd Annual Scientific Meeting set to kick-off virtually on June 3, 2021, Jessica Ailani, MD, FAHS, offered her perspective on what to expect from the presentations and sessions.

Living Up to the Gold Standard in Parkinson Disease: Jennifer S. Hui, MD

The assistant professor of neurology at the Keck School of Medicine at University of Southern California discussed the importance of having additional agents to treat Parkinson disease.

Remotely Screening and Evaluating Cognitive Impairment

Richard Gershon, PhD, vice chair for research at the Northwestern University Feinberg School of Medicine, discussed the development of the mobile toolbox battery to track cognitive decline.

Evaluating ATA188 in Progressive MS: Jakob Dupont, MD, MA

The head of global research and executive vice president of Atara Biotherapeutics discussed the trial design of part 2 of the study of ATA188.

Evaluating the aT2-LV Biomarker for MS: Robert Zivadinov, MD, PhD

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the findings of the post-hoc analysis of the ORATORIO study.

Accounting for Practice Effects on the MS Performance Test

Stephen Rao, PhD, ABPP-Cn, the Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic, discussed the development of the MSPT.

Assessing Atrophied Lesion Volume in Progressive MS: Robert Zivadinov, MD, PhD

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed the background of the ORATORIO study and the aT2-LV biomarker.

Characterizing Generalized Epilepsy in Elders: Vineet Punia, MD, MS

The neurologist at Cleveland Clinic discussed how his data may change clinicians’ perception on the management and prevalence of generalized epilepsy in elders.

Investigating Disparities in Post-Stroke Rehabilitation

Sana Somani, MD, MBBS, vascular neurology fellow at the University of Maryland Medical Center, discussed her research into disparities in post-stroke care.

Imaging Demonstrates Ocrelizumab’s Impact in Progressive MS: Robert Zivadinov, MD, PhD

The professor of neurology and director of the Buffalo Neuroimaging Analysis Center discussed his work on the ORATORIO study.

Patients With Chronic Migraine More Likely to Face Barriers to Successful Migraine Care

Monitoring Progression in Multiple Sclerosis: Stephen Rao, PhD, ABPP-Cn

The Ralph and Luci Schey Chair and Director of the Schey Center for Cognitive Neuroimaging at Cleveland Clinic discussed his investigations into improving the MSPT.

Improving Post-Stroke Outcomes With Personalized Discharge Instructions

Marian LaMonte, MD, MSN, FAAN, chief of neurology at Ascension Saint Agnes, discussed her team’s efforts to improve compliance in providing stroke discharge instructions.